Financial Performance - The company plans to distribute a cash dividend of 2.20 CNY per 10 shares (including tax) to all shareholders, with no bonus shares issued[4]. - The company's operating revenue for 2024 was CNY 4,027,010,847.67, representing a slight increase of 0.35% compared to CNY 4,013,164,370.86 in 2023[26]. - The net profit attributable to shareholders for 2024 decreased by 35.63% to CNY 428,640,508.53 from CNY 665,932,077.37 in 2023[26]. - The net profit after deducting non-recurring gains and losses for 2024 was CNY 408,760,889.53, down 38.29% from CNY 662,340,634.90 in 2023[26]. - The net cash flow from operating activities for 2024 was CNY 820,298,821.28, a decrease of 14.66% compared to CNY 961,242,697.69 in 2023[26]. - The total assets at the end of 2024 increased by 7.39% to CNY 7,924,043,231.64 from CNY 7,378,705,827.93 at the end of 2023[26]. - The net assets attributable to shareholders at the end of 2024 were CNY 5,794,409,772.57, reflecting a 2.46% increase from CNY 5,655,272,644.67 at the end of 2023[26]. - The basic earnings per share for 2024 were CNY 0.51, down 35.44% from CNY 0.79 in 2023[26]. - The company achieved a revenue of 4.027 billion yuan in 2024, representing a year-on-year growth of 0.35%, while the net profit attributable to shareholders decreased by 35.63% to 429 million yuan[68]. Business Strategy and Growth - The company is actively involved in the development of new medical technologies and products, aiming to improve patient care and operational efficiency[18]. - Future growth is anticipated through market expansion and the establishment of additional clinics and hospitals in strategic locations[18]. - The company is exploring potential mergers and acquisitions to strengthen its market position and diversify its service portfolio[18]. - The company is focused on expanding its network of eye hospitals and clinics across various regions, enhancing its market presence[19]. - The company aims to meet the standards for a tertiary hospital, which will enhance its service capabilities and attract more patients[19]. - The company is committed to improving operational efficiency through strategic management practices across its subsidiaries[17]. - The company is focused on internal growth and external acquisitions as part of its development strategy to sustain revenue growth and improve service quality[50]. - The company aims to enhance the revenue proportion from non-insured projects such as refractive, vision care, and dry eye treatments, focusing on consumer medical services[144]. - The company will continue to pursue an "internal growth + external mergers" strategy to enhance its national ophthalmology service network[144]. Market Trends and Opportunities - The overall market outlook remains positive, with expectations of increased healthcare spending and a rising prevalence of eye-related conditions driving demand for services[18]. - National policies in 2024 support the development of private hospitals and the application of AI in healthcare, which may benefit the company's operations[36]. - The market size of China's ophthalmology medical services is expected to reach RMB 252.15 billion by 2025, driven by policies for myopia prevention, aging population, and advancements in diagnostic technology[39]. - The incidence of cataracts among individuals aged 60 and above is approximately 80%, with projections indicating that the number of cataract patients will reach 241 million by 2050[43]. - The company is actively involved in the healthcare sector, focusing on ophthalmology, which is a growing market[19]. Research and Development - Investment in research and development is prioritized to innovate and enhance existing medical services and technologies[18]. - The company is exploring the role of dopamine receptor D2 (D2R) in myopia regulation, aiming to clarify the Wnt/β-catenin signaling pathway's involvement[91]. - The company is developing an AI-assisted system for age-related macular degeneration (AMD), targeting epidemiological survey-based solutions[91]. - The company is developing an artificial intelligence-assisted epidemiological screening algorithm model for AMD, aiming to establish a comprehensive evaluation and management system for risk factors and diseases[93]. - The company is conducting clinical research comparing femtosecond laser-assisted cataract surgery with traditional cataract surgery, focusing on postoperative visual acuity and corneal endothelial impact[99]. - The company is committed to advancing its research and development efforts in ophthalmology and related fields[110]. - The number of R&D personnel increased by 7.12% from 379 in 2023 to 406 in 2024[111]. - R&D investment amounted to ¥70,631,994.27 in 2024, representing 1.75% of operating revenue, up from 1.74% in 2023[112]. Operational Efficiency and Management - The company emphasizes a balanced development strategy integrating medical services, education, and research to continuously enhance its ophthalmic network and operational performance[50]. - The company has established a standardized service process for ophthalmic diagnosis and treatment, ensuring patient care is managed efficiently through a triage system and specialized consultations[53]. - The company has implemented a standardized surgical management process, which includes normal and special surgery approvals, aimed at minimizing surgical risks through strict classification and management[54][55]. - The company has established a market value management system to enhance investment value and investor returns, which was approved by the board of directors[164]. - The company has a complete business process and independent operational capabilities, ensuring no competition or unfair transactions with actual controllers[178]. Corporate Governance and Compliance - The company is committed to maintaining compliance with regulatory requirements set by the China Securities Regulatory Commission[19]. - The company has engaged Rongcheng Accounting Firm for auditing services, ensuring financial transparency[25]. - The company strictly adheres to information disclosure regulations, ensuring that all shareholders have equal access to information[170]. - The company actively manages investor relations through multiple channels, including a dedicated investor relations management system[171]. - The company respects the rights of shareholders, employees, suppliers, and patients while balancing interests and participating in public welfare activities[172]. Social Responsibility and Community Engagement - The company’s mission is to provide quality eye care services to all patients, regardless of their financial status, reflecting its commitment to social responsibility[50]. - The company has been recognized for its brand influence and social responsibility, actively participating in public welfare projects related to eye health[66]. - The company is focusing on the development of myopia prevention and control initiatives, launching multiple public welfare projects to address eye health issues among children and adolescents[66]. - The company plans to provide assistance to 100 economically disadvantaged individuals with corneal diseases over the next three years through its corneal transplant charity project[81].

Financial Performance - The company's revenue for Q1 2025 reached ¥1,093,056,547.55, representing an increase of 11.74% compared to ¥978,184,584.19 in the same period last year[5] - Net profit attributable to shareholders decreased by 4.00% to ¥149,673,716.87 from ¥155,917,808.87 year-on-year[5] - The net profit after deducting non-recurring gains and losses fell by 11.12% to ¥139,838,322.08 compared to ¥157,336,643.80 in the previous year[5] - Total revenue for the current period reached ¥1,093,056,547.55, an increase of 11.7% compared to ¥978,184,584.19 in the previous period[17] - Net profit for the current period was ¥165,298,507.95, slightly higher than ¥164,788,049.79 from the previous period, reflecting a growth of 0.3%[18] Cash Flow and Assets - Operating cash flow increased by 26.98% to ¥224,599,975.82 from ¥176,877,677.26 in the same period last year[5] - The company's total current assets as of March 31, 2025, amounted to RMB 4,898,393,552.36, an increase from RMB 4,789,035,311.56 at the beginning of the period[14] - The company's cash and cash equivalents decreased to RMB 870,405,287.23 from RMB 3,487,699,580.40 at the beginning of the period[14] - The company's trading financial assets increased significantly to RMB 3,123,355,508.41 from RMB 383,928,774.64[14] - The total comprehensive income attributable to minority shareholders was CNY 15,624,791.08, compared to CNY 8,870,240.92 in the previous period, indicating a significant increase[19] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 20,981, with the top ten shareholders holding a combined 73.43% of the shares[10] - The company has a significant shareholding structure, with the largest shareholder controlling 55.98% of the total shares[11] - Basic and diluted earnings per share both stood at CNY 0.18, slightly down from CNY 0.19 in the previous period[19] Investment and Expenses - Financial expenses increased by 92.60% to ¥10,902,395.38 due to rising leasing liabilities interest as the company expanded[8] - Other income rose significantly by 177.94% to ¥5,951,452.00, primarily due to increased government subsidies received during the reporting period[9] - Investment income surged by 234.84% to ¥7,508,769.79, attributed to the redemption of financial products during the period[9] - The company reported a decrease in research and development expenses to ¥15,539,755.73 from ¥17,303,375.36, a decline of 10.2%[17] Future Plans and Strategies - The company plans to repurchase shares using its own funds, with a total amount not less than RMB 150 million and not exceeding RMB 250 million, at a price not exceeding RMB 50.93 per share[12] - The company plans to expand its market presence and invest in new technologies to drive future growth[18] - The company is focusing on strategic acquisitions to enhance its competitive position in the market[18] Liabilities and Equity - Total assets at the end of the reporting period were ¥8,079,781,223.49, a 1.97% increase from ¥7,924,043,231.64 at the end of the previous year[5] - Non-current liabilities rose to ¥902,706,135.15, an increase of 3.1% from ¥870,570,443.20 in the last period[16] - The total equity attributable to shareholders reached ¥5,899,996,693.77, up from ¥5,794,409,772.57, indicating a growth of 1.8%[16]

证券代码：301267 证券简称：华厦眼科 公告编号：2025-008 华厦眼科医院集团股份有限公司 关于 2024 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、公司 2024 年度利润分配方案为：以实施权益分派股权登记日登记的公司 总股本扣除回购专用证券账户中的股份余额为基数（具体以公司权益分派实施公 告为准），向全体股东每 10 股派发现金红利人民币 2.20 元（含税），不送红股、 不以资本公积金转增股本。若在实施权益分派的股权登记日前，公司股本由于股 份回购、员工持股等情况发生变动的，公司将按照"分配比例不变"的原则，相 应调整分配总额。 2、公司现金分红方案不触及《深圳证券交易所创业板股票上市规则》第 9.4 条规定的可能被实施其他风险警示情形。 一、审议程序 华厦眼科医院集团股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日 召开第三届董事会第九次会议及第三届监事会第九次会议，审议并通过了《关于 2024 年度利润分配预案的议案》，该议案尚需提交公司 2024 年年度股东大会审 议。具体情 ...

资金流向方面，4月15日，华厦眼科主力资金净流出304.04万元，近5日总体呈流出状态，5日共流出 2187.76万元。 华厦眼科医院集团股份有限公司主营业务为眼科医疗服务，向眼科疾病患者提供各种眼科疾病的诊断、 治疗等眼科医疗服务。公司主要服务包括白内障专科、屈光专科、眼底病专科、眼表病专科、青光眼专 科、眼眶与眼肿瘤专科、眼外伤专科。公司已在国内开设51家眼科专科医院，覆盖17个省及45个城市， 辐射国内华东、华中、华南、西南、华北等广大地区，已通过连锁运营的模式建立了全国范围内的诊疗 服务网点体系。公司下属医院厦门大学附属厦门眼科中心获评国家三级甲等专科医院，获评国家临床重 点专科（眼科）建设单位，并设有博士后科研工作站和院士专家工作站。公司申请和开展了8项国家 级、10项省级科研课题；参与和开展临床试验项目13项，其中全国多中心项目担任总PI的项目2项；在 各类期刊发表科研论文196篇，其中SCI收录论文47篇。厦门眼科中心被厦门市科学技术局授予"厦门市 眼部疾病重点实验室"，被国家眼部疾病临床医学研究中心授予"一站式玻璃体腔注药实践示范基地"， 作为厦门唯一入列的医疗机构入选"2022年福建省儿童青 ...

中国国际金融股份有限公司 关于华厦眼科医院集团股份有限公司 2024 年度持续督导定期现场检查报告 （五）募集资金使用 现场检查手段： 对公司相关人员进行沟通、访谈；查阅公司募集资金管理制度及审批的三会文件；取得并查阅募集资 金专户银行对账单、募集资金使用明细，抽查大额募集资金支出的记账凭证及原始凭证；审阅与募投 项目相关的信息披露文件。 | 保荐人名称：中国国际金融股份有限公司 | 被保荐公司简称：华厦眼科 | | | | --- | --- | --- | --- | | 保荐代表人姓名：周凌轩 | 联系电话：010-65051166 | | | | 保荐代表人姓名：赵冀 | 联系电话：010-65051166 | | | | 现场检查人员姓名：赵冀、周凌轩 | | | | | 现场检查对应期间：2024 年度（"核查期间"） | | | | | 现场检查时间：2024 年 12 月 27 日 | | | | | 一、现场检查事项 | | 现场检查意见 | | | （一）公司治理 | 是 否 | | 不适用 | | 现场检查手段： | | | | | 对公司相关人员进行沟通、访谈；查阅公司董事会、监事会、 ...

华厦眼科医院集团股份有限公司 关于回购公司股份期限届满暨回购实施结果的公告 证券代码：301267 证券简称：华厦眼科 公告编号：2025-002 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 华厦眼科医院集团股份有限公司（以下简称"公司"）于 2024 年 1 月 8 日 召开了第三届董事会第五次会议和第三届监事会第五次会议，审议通过了《关于 回购公司股份方案的议案》，同意公司使用自有资金以集中竞价交易的方式回购 部分公司股份，用于实施员工持股计划或股权激励。本次回购股份的资金总额不 低于 1.5 亿元且不超过 2.5 亿元（均含本数）；回购价格不超过 50.93 元/股（含 本数），回购股份实施期限自公司董事会审议通过本次回购股份方案之日起 12 个月内。具体内容详见公司分别于 2024 年 1 月 9 日、2024 年 1 月 15 日在巨潮 资讯网（www.cninfo.com.cn）披露的《关于回购公司股份方案的公告》（公告编 号：2024-003）、《回购报告书》（公告编号：2024-005）。 公司 2023 年年度权益分派实施后，按照相关规定 ...

华厦眼科医院集团股份有限公司 关于回购公司股份进展的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 华厦眼科医院集团股份有限公司（以下简称"公司"）于 2024 年 1 月 8 日 召开了第三届董事会第五次会议和第三届监事会第五次会议，审议通过了《关于 回购公司股份方案的议案》，同意公司使用自有资金以集中竞价交易的方式回购 部分公司股份，用于实施员工持股计划或股权激励。本次回购股份的资金总额不 低于 1.5 亿元且不超过 2.5 亿元（均含本数）；回购价格不超过 50.93 元/股（含 本数），回购股份实施期限自公司董事会审议通过本次回购股份方案之日起 12 个月内。具体内容详见公司分别于 2024 年 1 月 9 日、2024 年 1 月 15 日在巨潮 资讯网（www.cninfo.com.cn）披露的《关于回购公司股份方案的公告》（公告编 号：2024-003）、《回购报告书》（公告编号：2024-005）。 公司 2023 年年度权益分派实施后，按照相关规定对回购股份价格上限进行 相应调整，回购股份价格上限由 50.93 元/股调整为 50.82 ...

关于回购公司股份进展的公告 截至 2024 年 11 月 30 日，公司通过股份回购证券专用账户以集中竞价交易 方式累计回购公司股份 6,581,440 股，占公司目前总股本的 0.78%，最高成交价 为 30.93 元/股，最低成交价为 19.38 元/股，累计成交总金额为 18,130.20 万元（不 含交易费用）。本次回购符合相关法律法规的要求，符合公司既定的回购方案。 1 二、其他说明 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 华厦眼科医院集团股份有限公司（以下简称"公司"）于 2024 年 1 月 8 日 召开了第三届董事会第五次会议和第三届监事会第五次会议，审议通过了《关于 回购公司股份方案的议案》，同意公司使用自有资金以集中竞价交易的方式回购 部分公司股份，用于实施员工持股计划或股权激励。本次回购股份的资金总额不 低于 1.5 亿元且不超过 2.5 亿元（均含本数）；回购价格不超过 50.93 元/股（含 本数），回购股份实施期限自公司董事会审议通过本次回购股份方案之日起 12 个月内。具体内容详见公司分别于 2024 年 1 月 9 日、 ...

Investment Rating - The investment rating for the company is "Buy" and is maintained [4]. Core Views - The company's performance is in line with expectations but is under short-term pressure due to consumer constraints. For the first three quarters of 2024, the company reported revenue of 3.182 billion yuan, a year-on-year increase of 2.55%. However, the net profit attributable to the parent company decreased by 24.49% to 421 million yuan [4][5]. - The company is optimistic about a recovery in consumer spending, which is expected to accelerate performance in the future. The gross margin has shown continuous improvement, with a gross margin of 46.39% in Q3 2024 [4][5]. Summary by Sections Financial Performance - In Q3 2024, the company achieved revenue of 1.131 billion yuan, a year-on-year increase of 2.00%. The net profit attributable to the parent company for this quarter was 155 million yuan, down 23.35% year-on-year [4]. - The company has projected revenues of 4.194 billion, 4.823 billion, and 5.643 billion yuan for 2024, 2025, and 2026 respectively, with net profits of 635 million, 745 million, and 909 million yuan for the same years [6]. Strategic Initiatives - The company is deepening its "medical education and research collaborative development" strategy and optimizing its talent cultivation mechanism. It has established a comprehensive medical education research system and formed partnerships with over 30 universities, training more than 1,500 students and creating a dual-teacher expert team of 110 members [5]. - The company is expanding its service network through strategic acquisitions, including hospitals in Chengdu and other locations, enhancing its diagnostic and treatment capabilities [5]. Industry Positioning - The company is enhancing its service level by introducing advanced medical equipment, such as the first 3D digital navigation surgical microscope in China, which improves the precision of ophthalmic surgeries [6]. - The current stock price is 22.60 yuan, with a total share capital of 84 million shares. The price-to-earnings ratio for the projected years is 30, 25, and 21 times for 2024, 2025, and 2026 respectively [8].

Investment Rating - The report maintains a "Recommended" rating for the company with a target price of 27 yuan, while the current price is 22.60 yuan [1][3]. Core Insights - The company reported a slight increase in revenue of 2.55% year-on-year for the first three quarters of 2024, totaling 3.182 billion yuan, but a significant decline in net profit by 24.49% to 421 million yuan [1][2]. - The third quarter alone saw a revenue of 1.131 billion yuan, reflecting a 2% increase year-on-year, but net profit decreased by 23.35% to 155 million yuan [1][2]. - The revenue pressure is attributed to the implementation of DRG/DIP medical insurance settlement methods in some regions, which has affected the average price of cataract surgeries, and a general decline in consumer spending impacting refractive and optical services [2]. - The company has managed to keep its costs under control, achieving a gross margin of 46.39% in Q3 2024, although this represents a decline of 4.8 percentage points year-on-year due to expenses related to the establishment of new hospitals [2]. Financial Summary - For 2024, the company’s projected net profit is adjusted to 562 million yuan, a decrease of 15.6% year-on-year, with forecasts for 2025 and 2026 at 637 million yuan and 688 million yuan, respectively [3][4]. - The total revenue projections for 2024, 2025, and 2026 are 4.194 billion yuan, 4.516 billion yuan, and 4.893 billion yuan, with year-on-year growth rates of 4.5%, 7.7%, and 8.4% respectively [4][7]. - The earnings per share (EPS) are expected to be 0.67 yuan for 2024, 0.76 yuan for 2025, and 0.82 yuan for 2026, with corresponding price-to-earnings (P/E) ratios of 34, 30, and 28 [4][7].